Stock Track | Praxis Precision Medicines Soars 5.50% as Chardan Capital Initiates Coverage with Buy Rating and $80 Price Target

Stock Track

May 08, 2025

Shares of Praxis Precision Medicines, Inc. (PRAX) are soaring 5.50% in intraday trading on Wednesday, following a positive initiation from Chardan Capital. The stock's significant jump comes as investors react to the new bullish stance from a respected research firm.

Chardan Capital has initiated coverage on Praxis Precision Medicines with a Buy rating, setting an ambitious price target of $80. This new target represents substantial upside potential from the stock's current trading levels, fueling investor optimism and driving the sharp increase in share price.

The positive sentiment from Chardan Capital aligns with the overall bullish view on Praxis Precision Medicines among Wall Street analysts. According to FactSet data, the company currently maintains an average rating of Buy from analysts, with a mean price target of $99.27. This consensus suggests that other analysts also see significant growth potential for the biopharmaceutical company, which specializes in developing therapies for central nervous system disorders.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1179643202"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1179643202\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1179643202?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-08 00:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179643202","market":"sg","top_or_hot":-1,"title":"Stock Track | Praxis Precision Medicines Soars 5.50% as Chardan Capital Initiates Coverage with Buy Rating and $80 Price Target","media":"Stock Track","content":"<p>Shares of Praxis Precision Medicines, Inc. (PRAX) are soaring 5.50% in intraday trading on Wednesday, following a positive initiation from Chardan Capital. The stock's significant jump comes as investors react to the new bullish stance from a respected research firm.</p>\n\n<p>Chardan Capital has initiated coverage on Praxis Precision Medicines with a Buy rating, setting an ambitious price target of $80. This new target represents substantial upside potential from the stock's current trading levels, fueling investor optimism and driving the sharp increase in share price.</p>\n\n<p>The positive sentiment from Chardan Capital aligns with the overall bullish view on Praxis Precision Medicines among Wall Street analysts. According to FactSet data, the company currently maintains an average rating of Buy from analysts, with a mean price target of $99.27. This consensus suggests that other analysts also see significant growth potential for the biopharmaceutical company, which specializes in developing therapies for central nervous system disorders.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Praxis Precision Medicines Soars 5.50% as Chardan Capital Initiates Coverage with Buy Rating and $80 Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Praxis Precision Medicines Soars 5.50% as Chardan Capital Initiates Coverage with Buy Rating and $80 Price Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-05-08 00:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Praxis Precision Medicines, Inc. (PRAX) are soaring 5.50% in intraday trading on Wednesday, following a positive initiation from Chardan Capital. The stock's significant jump comes as investors react to the new bullish stance from a respected research firm.</p>\n\n<p>Chardan Capital has initiated coverage on Praxis Precision Medicines with a Buy rating, setting an ambitious price target of $80. This new target represents substantial upside potential from the stock's current trading levels, fueling investor optimism and driving the sharp increase in share price.</p>\n\n<p>The positive sentiment from Chardan Capital aligns with the overall bullish view on Praxis Precision Medicines among Wall Street analysts. According to FactSet data, the company currently maintains an average rating of Buy from analysts, with a mean price target of $99.27. This consensus suggests that other analysts also see significant growth potential for the biopharmaceutical company, which specializes in developing therapies for central nervous system disorders.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRAX","symbol_name":"Praxis Precision Medicines, Inc.","start_time":0,"source_url":"","article_id":"1179643202","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179643202","pubTimestamp":1746634468,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Praxis Precision Medicines, Inc.  are soaring 5.50% in intraday trading on Wednesday, following a positive initiation from Chardan Capital. The stock's significant jump comes as investors react to the new bullish stance from a respected research firm.Chardan Capital has initiated coverage on Praxis Precision Medicines with a Buy rating, setting an ambitious price target of $80. This new target represents substantial upside potential from the stock's current trading levels, fueling inve","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PRAX":"Praxis Precision Medicines, Inc."},"translate_title":"Chardan Capital首次给予买入评级和80美元目标价，Praxis Precision Medicines股价飙升5.50%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRAX":1},"content_text":"Shares of Praxis Precision Medicines, Inc. (PRAX) are soaring 5.50% in intraday trading on Wednesday, following a positive initiation from Chardan Capital. The stock's significant jump comes as investors react to the new bullish stance from a respected research firm.\nChardan Capital has initiated coverage on Praxis Precision Medicines with a Buy rating, setting an ambitious price target of $80. This new target represents substantial upside potential from the stock's current trading levels, fueling investor optimism and driving the sharp increase in share price.\nThe positive sentiment from Chardan Capital aligns with the overall bullish view on Praxis Precision Medicines among Wall Street analysts. According to FactSet data, the company currently maintains an average rating of Buy from analysts, with a mean price target of $99.27. This consensus suggests that other analysts also see significant growth potential for the biopharmaceutical company, which specializes in developing therapies for central nervous system disorders.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}